Empyrean Therapeutics Acquires TLR-2 Antagonist Molecule From Eos Therapies to Advance and Commercialize Breakthrough Cancer Treatment
Online, November 25, 2024 (Ecnetnews.com) - Empyrean Therapeutics, Inc., a pioneering biopharmaceutical company, today announced the successful acquisition of a ...